All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Tolero Pharmaceuticals Inc., of Salt Lake City, presented preclinical data on TP-0903, an AXL kinase inhibitor shown to sensitize cancer cells to various immuno-oncology agents, including an immune checkpoint inhibitor.